Incobotulinumtoxin A is a botulinum toxin type A drug without complexing proteins.
Treatment of spasticty, cervical dystonia, benign essential blepharospasm and glabellar lines
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
M MUSCULO-SKELETAL SYSTEM
M03 MUSCLE RELAXANTS
M03A MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
M03AX Other muscle relaxants, peripherally acting agents
M03AX01 Botulinum toxin
D10012 Incobotulinumtoxin A (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Dermatological Agents
Dermatological Agents, Other
Dermatological Agents, Miscellaneous
Incobotulinumtoxin A
D10012 Incobotulinumtoxin A (JAN/USAN)
Skeletal Muscle Relaxants
Incobotulinumtoxin A
D10012 Incobotulinumtoxin A (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
12 Agents affecting peripheral nervous system
122 Skeletal muscle relaxants
1229 Others
D10012 Incobotulinumtoxin A (JAN/USAN)
129 Miscellaneous
1290 Miscellaneous
D10012 Incobotulinumtoxin A (JAN/USAN)
Drug groups [BR:br08330]
Musculo-skeletal system agent
DG02029 Muscle relaxant
DG01696 Peripherally-acting muscle relaxant
DG03117 Nondepolarizing neuromuscular blocking agent
DG00772 Botulinum toxin
D10012 Incobotulinumtoxin A
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Organismal systems
Nervous system
SNAP25
D10012 Incobotulinumtoxin A (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10012
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10012
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10012
Drug groups [BR:br08330]
Musculo-skeletal system agent
DG02029 Muscle relaxant
DG01696 Peripherally-acting muscle relaxant
DG03117 Nondepolarizing neuromuscular blocking agent
DG00772 Botulinum toxin
